A new memorandum of understanding has been signed by Karolinska ATMP Center and the ATMP Center Uppsala to deepen their collaboration in the rapidly growing field of advanced therapy medicinal products (ATMPs), which includes cell- and gene-based medicines. The aim is to enhance joint capacity and competitiveness in the Stockholm-Uppsala region.
This new agreement builds on a previous commitment to strengthen the shared life science cluster in the Stockholm-Uppsala region. The long-term goal is to position the region as one of the world's leading hubs in life sciences.
In conjunction with the launch of the collaboration, a new report was also presented, highlighting how the Stockholm-Uppsala region is advancing ATMP development through strategic partnerships, clinical trials, and in-house manufacturing.
Read the report "Stockholm-Uppsala Life Science Cluster" (in Swedish)
"Through this partnership, we are enhancing our ability to scale up and reach more patients with innovative treatments," says Knut Steffensen, Director of the Karolinska ATMP Center.
Focus areas of the collaboration
The Karolinska and Uppsala ATMP centres have agreed to intensify their joint efforts in the development and production of advanced therapy medicinal products, including in-house CAR-T manufacturing, as well as the implementation of clinical trials and treatments. The collaboration also includes joint training initiatives and the exchange of knowledge and experience. Furthermore, the parties aim to strengthen international partnerships and engage with micro-enterprises and small and medium-sized enterprises (SMEs) to foster innovation and growth in the ATMP sector.
